Teresa Klinowska - Concepedia

Author

Teresa Klinowska

Also Known As

T Klinowska, T. Klinowska, T.C.M. Klinowska, TERESA KLINOWSKA, Teresa C. Klinowska, Teresa C. M. Klinowska, Teresa C.M. Klinowska, Teresa CM Klinowska, Teresa Klinowska

248

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)University of Manchester AstraZeneca (United States)Sarah Cannon The Christie NHS Foundation Trust

About

Teresa Klinowska is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	33	2.9K
2	Natural Sciences	9	9	421
3	Biochemistry	7	7	397
4	Health Sciences	4	4	112
5	Biomolecular Engineering	2	2	26

Teresa Klinowska

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu, Cancer Discovery	2014	2.2K
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton, Journal of Medicinal Chemistry GeneticsPathologyClinical CandidateTumor BiologyT790m Resistance Mutations	2014	590
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family Paul R. Gavine, Lorraine Mooney, Elaine Kilgour, Cancer Research Fgfr SelectivityKinase InhibitorsPharmacotherapyTumor BiologySignaling Pathway	2012	491
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor Vanessa Rodrik-Outmezguine, Masanori Okaniwa, Zhan Yao, Nature MedicineMtor Resistance MutationsMolecular BiologyResistance Mutation (Virology)Pharmacology	2016	469
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) Richard A. Ward, Mark J. Anderton, Susan Ashton, Journal of Medicinal Chemistry Covalent InhibitorsDrug TargetThiol ReactivityTyrosine KinaseMolecular Biology	2013	257
Laminin and β1 Integrins Are Crucial for Normal Mammary Gland Development in the Mouse Teresa Klinowska, Jesús V. Soriano, Gwynneth M. Edwards, Developmental Biology Developmental BiologyTissue DevelopmentMammary GlandCell-matrix InteractionMorphogenesis	1999	136
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Molecular Cancer Therapeutics Breast OncologyChemoprevention StrategyPharmacotherapyMtorc1 ComplexTumor Biology	2015	125
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer D. Mark Hickinson, Teresa Klinowska, Georgina Speake, Clinical Cancer Research	2010	118
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist James S. Scott, Amber Balazs, Bernard Barlaam, Journal of Medicinal Chemistry	2020	109
Developmental regulation of Bcl-2 family protein expression in the involuting mammary gland Anthony D. Metcalfe, Andrew Gilmore, Teresa Klinowska, Journal of Cell Science	1999	97

Page 1